07/30/2025
Treatment-Resistant Depression (TRD): Spravato is specifically approved for adults with depression who haven't responded adequately to at least two different antidepressant treatments. This provides a new option for individuals who have struggled to find effective relief with traditional antidepressants.
Rapid Relief of Symptoms: Spravato has demonstrated a more rapid onset of action compared to traditional antidepressants, with some patients experiencing improvement within hours or days of treatment, according to Spravato. This can be particularly beneficial for individuals experiencing severe or debilitating depressive symptoms.
Major Depressive Disorder with Suicidal Thoughts or Actions: Spravato is also approved for the treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior. Studies have shown it can rapidly reduce suicidal ideation, providing a critical window for intervention and support.
Different Mechanism of Action: Unlike traditional antidepressants that primarily target serotonin, norepinephrine, or dopamine, Spravato works on the glutamate system and NMDA receptors in the brain. This unique mechanism may offer hope for those who haven't found success with conventional approaches.
Convenience of Administration: Spravato is administered as a nasal spray in a supervised healthcare setting. This may be preferable for some individuals who have difficulty swallowing pills.
